FDA issues warning after patient dies following fecal transplant

Scanning electron micrograph of various bacteria found in a sample of human faeces.

Steve Gschmeissner | Science Photo Library | Getty Images

The Food and Drug Administration on Thursday issued a safety warning following the death of a patient who contracted a drug resistant bacteria that was transmitted during an experimental fecal transplant.

Another patient also fell ill after receiving a transplant, the FDA said. Both adults, who the agency did not identify, had compromised immune systems.

The stool used for both patients’ transplants was obtained from the same donor, according to the FDA, and was not tested for E.coli bacteria that produced the beta-lactamase enzyme. An FDA spokeswoman could not immediately provide more details on the death.

“While we support this area of scientific discovery, it’s important to note that FMT does not come without risk,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement. The FDA said the patient who died received an experimental fecal microbiome transplant, or FMT. “We therefore want to alert all health care professionals who administer FMT about this potential serious risk so they can inform their patients,” he said.

The FDA said certain donor screening and stool testing protections are needed for any experimental use of fecal microbiome transplants as a result of the patients falling ill.

Fecal microbiome transplants, also known as stool transplants, are when fecal bacteria from healthy donors are transplanted into a recipient. The FDA has permitted the experimental transplants to be used for certain conditions since 2013.

Products You May Like

Articles You May Like

Craig Wright Faces Perjury Investigation Over Claims He Created Bitcoin
The AI-Powered Future of Coding Is Near
The Architect of Russia’s Google Is Back
The Global CrowdStrike Outage Triggered a Surprise Return to Cash
OpenAI Touts New AI Safety Research. Critics Say It’s a Good Step, but Not Enough

Leave a Reply